Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Ultragenyx first quarter 2026 financial results conference call. At this time, all participants are on a listen-only mode. At the end of the prepared remarks, you will have an opportunity to ask questions during the Q&A portion of the call. It is now my pleasure to introduce your host, Joshua Higa, Vice President of Investor Relations. Thank you. We have issued a press release detailing our financial results, which you can find on our website at Ultragenyx.com. Joining me on this call are Emil Kakas, Chief Executive Officer and President, Eric Harris, Chief Commercial Officer, Howard Horn, Chief Financial Officer, and Eric Kronbez, Chief Medical Officer. I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings. I'll now turn the call over to Emil. Thanks, Josh, and good afternoon, everyone. We are now in our 16th year since our founding, and this year is expected to be transformative with growing revenue and multiple new drug approvals. We're on track to well exceed $700 million in revenue from our global commercial business with a consistent track record of double-digit annual revenue growth. We have a baduka date for two gene therapies that would bring first-ever treatments to patients and families with no other disease-monifying options. Also, we'll unwind our phase three ASPIRE study, evaluating GTX102 in patients with Angelman syndrome in the second half of this year. We continue to execute global clinical trials across the largest late-stage pipeline in rare diseases. We're also manufacturing our gene therapy pro...